TRX 818

Drug Profile

TRX 818

Alternative Names: CVM-1118; TRX-818

Latest Information Update: 16 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TaiRx
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Growth inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer
  • Phase I Cancer; Solid tumours

Most Recent Events

  • 14 Aug 2018 Chemical structure information added
  • 25 Jul 2018 TaiRx plans a phase II trial for Neuroendocrine tumors (Unresectable, Metastatic-disease, Second-line therapy or greater) in Taiwan in November 2018 (NCT03600233)
  • 13 Jul 2018 TaiRx plans a phase II trial in Hepatocellular carcinoma(Late-stage disease, Combination therapy, First line therapy) in the US and Taiwan (PO, Capsule) (NCT03582618)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top